 |
|
|
| |
Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested US clinical samples: 2006 to 2012
|
| |
| |
Reported by Jules Levin
CROI 2013
Erkki Lathouwers,1 Chrispin Kambili,2 Mojgan Haddad,3 Agnes Paquet,3 Sandra De Meyer,1 Bryan Baugh4
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Global Services, Titusville, NJ, USA; 3Monogram Biosciences, South San Francisco, CA, USA; 4Janssen Therapeutics, Titusville, NJ, USA
|
| |
|
|
|
|
|
